Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
-12
¥ million (year-on-year comparison with the previous fiscal year's actual net sales for the fiscal year ending December 2026)Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
FormulatedWhat happened to the previous planNet sales of ¥80 million, operating profit of ¥(1,040) million, and net income of ¥(1,095) million (earnings forecast for the fiscal year ending December 2025) → Net sales of ¥83 million, operating profit of ¥(1,046) million, and net income of ¥(1,104) million (actual results for the fiscal year ended December 2025)0.0%Calculated from the two disclosed figures
Total investment plan¥3,256 million (total allocation plan for the 25th Series of Stock Acquisition Rights, including research and development, development, manufacturing and operations of equipment products, and working capital)
Investment amount by sectorField Clinical trial expenses for the development of allogeneic cartilage cell sheets / Amount ¥1,790 million, Field Operating funds for cell culture facilities for the development of allogeneic cartilage cell sheets / Amount ¥294 million, Field Development and operating expenses for the equipment business / Amount ¥474 million, Field Head office operating expenses and other costs / Amount ¥698 million
Key initiatives
01The Company will actively promote its equipment products to improve awareness among overseas researchers and seek to further expand overseas sales.
02The Company will accelerate the overseas rollout of UpCell flasks, products suited to the large-scale culture and harvesting of cells, for which global demand is expanding.
03Through contract manufacturing and consulting services for specified cell-processed products, the Company aims to expand its customer base in the private-pay medical care sector and secure recurring revenue.
04The Company will focus on securing new contract projects by actively developing sales activities as a CDMO.
05The Company will work closely with medical institutions to enroll cases as planned and consider adding sites as necessary.
06The Company will continue producing master cell banks and working cell banks to ensure a stable supply of products after commercialization.
07The Company will work to introduce automation and systems to improve the efficiency of post-commercialization product manufacturing.
08The Company will develop its internal structure for obtaining marketing approval.
09The Company will explore new pipeline candidates and consider specific plans for their development.
10To accelerate commercialization and prepare for the future sale of allogeneic cartilage cell sheets, the Company will continue to actively pursue activities aimed at entering into business alliances and joint research agreements with multiple companies.
Plan assumptionsIn the cell culture equipment business, the Company assumes that the impact of trends in overseas research institutions' budgets and geopolitical risks on research activities may continue to a certain extent., In the regenerative medicine contract services business, the Company will focus on securing new contract manufacturing orders from medical institutions and companies.
Non-financial targetsIndicator name High rate of parental leave utilization / Target value Achieve a high utilization rate (currently 100% for both men and women) / Timing VISION2030
Size of the Target MarketDomestic market Estimated at ¥850 billion in 2030 and ¥1.1 trillion in 2040 / Global market Estimated at ¥7.5 trillion in 2030 and ¥12 trillion in 2040 / Source Japan Agency for Medical Research and Development (AMED), Final Report on the FY2019 Market Survey of Regenerative Medicine and Gene Therapy
Risks identified by the company
Declining profitability if the high price level of cell culture equipment requires price reductions as a result of sales promotion policies or other measures
The continuation of geopolitical instability and unexpected reductions in research funding and research personnel directly leading to a decline in research activities
Cancellation of contract work or delays in monetization resulting from delays in the contracting party's development activities or changes in its policies
Declining profitability if the number of contracts decreases because of the contracting party's ability to attract patients
The time and substantial costs required because the regenerative medicine business remains under development and lacks an established business foundation
Delays in patient enrollment because of restrictions on participant eligibility
Delays in regulatory applications resulting from the time required to select alliance partners
Increased funding needs arising from working capital, research and development investment, capital investment, and other expenditures associated with advancing research and development activities
| Item | Details |
|---|---|
| Plan name | VISION2030 |
| Plan period | Start year: Not disclosed; final year: 2030 |
| Progress against the plan | Formulated |
| Total investment plan | ¥3,256 million (total allocation plan for the 25th Series of Stock Acquisition Rights, including research and development, development, manufacturing and operations of equipment products, and working capital) |
| Investment amount by sector | Field Clinical trial expenses for the development of allogeneic cartilage cell sheets / Amount ¥1,790 million, Field Operating funds for cell culture facilities for the development of allogeneic cartilage cell sheets / Amount ¥294 million, Field Development and operating expenses for the equipment business / Amount ¥474 million, Field Head office operating expenses and other costs / Amount ¥698 million |
| Non-financial targets | Indicator name High rate of parental leave utilization / Target value Achieve a high utilization rate (currently 100% for both men and women) / Timing VISION2030 |
| Plan assumptions | In the cell culture equipment business, the Company assumes that the impact of trends in overseas research institutions' budgets and geopolitical risks on research activities may continue to a certain extent., In the regenerative medicine contract services business, the Company will focus on securing new contract manufacturing orders from medical institutions and companies. |
| Key initiatives | The Company will actively promote its equipment products to improve awareness among overseas researchers and seek to further expand overseas sales., The Company will accelerate the overseas rollout of UpCell flasks, products suited to the large-scale culture and harvesting of cells, for which global demand is expanding., Through contract manufacturing and consulting services for specified cell-processed products, the Company aims to expand its customer base in the private-pay medical care sector and secure recurring revenue., The Company will focus on securing new contract projects by actively developing sales activities as a CDMO., The Company will work closely with medical institutions to enroll cases as planned and consider adding sites as necessary., The Company will continue producing master cell banks and working cell banks to ensure a stable supply of products after commercialization., The Company will work to introduce automation and systems to improve the efficiency of post-commercialization product manufacturing., The Company will develop its internal structure for obtaining marketing approval., The Company will explore new pipeline candidates and consider specific plans for their development., To accelerate commercialization and prepare for the future sale of allogeneic cartilage cell sheets, the Company will continue to actively pursue activities aimed at entering into business alliances and joint research agreements with multiple companies. |
| Results under the previous plan | Net sales of ¥80 million, operating profit of ¥(1,040) million, and net income of ¥(1,095) million (earnings forecast for the fiscal year ending December 2025) → Net sales of ¥83 million, operating profit of ¥(1,046) million, and net income of ¥(1,104) million (actual results for the fiscal year ended December 2025) |
| Size of the Target Market | Domestic market Estimated at ¥850 billion in 2030 and ¥1.1 trillion in 2040 / Global market Estimated at ¥7.5 trillion in 2030 and ¥12 trillion in 2040 / Source Japan Agency for Medical Research and Development (AMED), Final Report on the FY2019 Market Survey of Regenerative Medicine and Gene Therapy |
| Risks identified | Declining profitability if the high price level of cell culture equipment requires price reductions as a result of sales promotion policies or other measures, The continuation of geopolitical instability and unexpected reductions in research funding and research personnel directly leading to a decline in research activities, Cancellation of contract work or delays in monetization resulting from delays in the contracting party's development activities or changes in its policies, Declining profitability if the number of contracts decreases because of the contracting party's ability to attract patients, The time and substantial costs required because the regenerative medicine business remains under development and lacks an established business foundation, Delays in patient enrollment because of restrictions on participant eligibility, Delays in regulatory applications resulting from the time required to select alliance partners, Increased funding needs arising from working capital, research and development investment, capital investment, and other expenditures associated with advancing research and development activities |
| Publication date | March 2026 |
Items this document does not state (13)
Sales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceSegment targetReason for revision or withdrawalDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To establish a new Mission & Vision on the occasion of the Company's 25th anniversary and contribute to the further development of regenerative medicine as it expands globally. The Company has adopted a cautious sales plan for the fiscal year ending December 2026, taking into account the possibility that trends in overseas research institutions' budgets and the impact of geopolitical risks on research activities may continue.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.